Literature DB >> 16985716

Prostate cancer gene therapy-what have we learned and where are we going?

B Djavan, Y Nasu.   

Abstract

With recent advances in genetic engineering, tumor biology, and immunology, gene therapy has been recognized as a promising new treatment option for various cancers, including prostate cancer. Several clinical trials of prostate cancer gene therapy, using therapeutic genes which include suicide genes, immunomodulatory genes, tumor suppressor genes, and anti-oncogenes, are under way and preliminary reports have emerged. Although gene therapy for prostate cancer is still at an early stage and requires additional technological breakthroughs, new insights obtained from recent clinical trials indicate a promising potential for prostate cancer gene therapy. In this report, general concepts, current progress, and future prospects in prostate cancer gene therapy are summarized.

Entities:  

Year:  2001        PMID: 16985716      PMCID: PMC1476064     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  29 in total

1.  Reports of adenovector "death" are greatly exaggerated.

Authors:  M Brenner
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

Review 2.  Prostate cancer gene therapy: outcome of basic research and clinical trials.

Authors:  Y Nasu; B Djavan; M Marberger; H Kumon
Journal:  Tech Urol       Date:  1999-12

Review 3.  Gene therapy for prostate cancer.

Authors:  K Sikora; H Pandha
Journal:  Br J Urol       Date:  1997-04

4.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

Review 5.  Biological principles and clinical development of prostate cancer gene therapy.

Authors:  M G Sanda
Journal:  Semin Urol Oncol       Date:  1997-02

6.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

Authors:  J R Herman; H L Adler; E Aguilar-Cordova; A Rojas-Martinez; S Woo; T L Timme; T M Wheeler; T C Thompson; P T Scardino
Journal:  Hum Gene Ther       Date:  1999-05-01       Impact factor: 5.695

7.  Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer.

Authors:  S J Hall; S E Mutchnik; S H Chen; S L Woo; T C Thompson
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

8.  Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.

Authors:  J A Eastham; S H Chen; I Sehgal; G Yang; T L Timme; S J Hall; S L Woo; T C Thompson
Journal:  Hum Gene Ther       Date:  1996-03-01       Impact factor: 5.695

9.  Gene therapy for prostate cancer.

Authors:  J Naitoh; A Belldegrun
Journal:  Prostate Cancer Prostatic Dis       Date:  1998-06       Impact factor: 5.554

10.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

View more
  6 in total

1.  Synthesis and antiproliferative and apoptosis-inducing activity of novel 3-substituted-3-hydroxy-2-oxindole compounds.

Authors:  Mona Nazemi Moghaddam; Razieh Jalal; Zohreh Zeraatkar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-11-09       Impact factor: 2.416

2.  3D Porous Chitosan-Alginate Scaffolds as an In Vitro Model for Evaluating Nanoparticle-Mediated Tumor Targeting and Gene Delivery to Prostate Cancer.

Authors:  Kui Wang; Forrest M Kievit; Stephen J Florczyk; Zachary R Stephen; Miqin Zhang
Journal:  Biomacromolecules       Date:  2015-09-16       Impact factor: 6.988

Review 3.  Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells.

Authors:  Ravi Pathak; Marc Philizaire; Shiraz Mujtaba
Journal:  Cancers (Basel)       Date:  2015-08-19       Impact factor: 6.639

4.  Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.

Authors:  Bo-Rim Yi; Kyung-A Hwang; Yun-Bae Kim; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Mol Sci       Date:  2012-09-28       Impact factor: 5.923

5.  Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer.

Authors:  Xu Zhang; Wenrong Xu; Hui Qian; Wei Zhu; Ruiwen Zhang
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

Review 6.  Potential Applications of Nanotechnology in Urological Cancer.

Authors:  Ming-Hui He; Li Chen; Ting Zheng; Yu Tu; Qian He; Hua-Lin Fu; Ju-Chun Lin; Wei Zhang; Gang Shu; Lili He; Zhi-Xiang Yuan
Journal:  Front Pharmacol       Date:  2018-07-09       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.